Literature DB >> 30354576

Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points.

Stephen J Greene1,2, Adrian F Hernandez1,2, Jie-Lena Sun1, Javed Butler3, Paul W Armstrong4, Justin A Ezekowitz4, Faiez Zannad5, João Pedro Ferreira5, Adrian Coles1, Marco Metra6, Adriaan A Voors7, Robert M Califf1,2, Christopher M O'Connor1,8, Robert J Mentz1,2.   

Abstract

BACKGROUND: Globalization of clinical trials fosters inclusion of higher and lower income countries, but the influence of enrolling country income level on heart failure trial performance is unclear. This study sought to evaluate associations between enrolling country income level, acute heart failure patient profile, protocol completion, and trial end points. METHODS AND
RESULTS: The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial included 7141 patients with acute heart failure from 30 countries. Country income data in gross national income per capita in current US dollars from the year 2007 (ie, the year trial enrollment began) were abstracted from the World Bank. Patients were grouped by enrolling country income level (ie, high [>$11 455], upper middle [$3706-$11 455], lower middle [$936-$3705], and low [<$936]). Income data were available for 29 (97%) countries (N=7064). There were 3996 (57%), 1518 (21%), and 1550 (22%) patients from high-income, upper-middle-income, and lower-middle-income countries, respectively. There were no patients from low-income countries. Patients from lower-middle-income countries tended to be younger with fewer comorbidities and lower utilization of guideline-directed therapies. Rates of adverse events (13.8%) and protocol noncompletion (4.9%) during 180-day follow-up were highest among high-income countries (all P <0.01). After adjustment for race, geographic region, and clinical characteristics, compared with lower-middle-income countries, enrollment from higher income countries was associated with increased 30-day mortality or rehospitalization (high income: odds ratio, 1.70; 95% CI, 1.02-2.85; upper-middle-income: odds ratio, 2.16; 95% CI, 1.23-3.81), driven by higher rates of rehospitalization. Mortality was similar at 30 and 180 days. The association between higher country income and the 30-day composite end point was similar across geographic regions, with exception of Latin America ( P for interaction, 0.03).
CONCLUSIONS: In this global acute heart failure trial, patients from higher income countries had lower rates of protocol completion, higher rates of adverse events, and similar mortality rates. After adjustment for race, geographic region, and clinical factors, enrollment from a higher income country was associated with worse clinical outcomes, driven by higher rates of rehospitalization. Variation in enrolling country income level may influence study end points and trial performance independent of geographic region. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00475852.

Entities:  

Keywords:  clinical trial; heart failure; hospitalization; income

Mesh:

Substances:

Year:  2018        PMID: 30354576      PMCID: PMC6208149          DOI: 10.1161/CIRCOUTCOMES.118.004783

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  24 in total

1.  Ethical and scientific implications of the globalization of clinical research.

Authors:  Seth W Glickman; John G McHutchison; Eric D Peterson; Charles B Cairns; Robert A Harrington; Robert M Califf; Kevin A Schulman
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

2.  International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute.

Authors:  Esther S H Kim; Thomas P Carrigan; Venu Menon
Journal:  J Am Coll Cardiol       Date:  2011-08-09       Impact factor: 24.094

3.  Effect of nesiritide in patients with acute decompensated heart failure.

Authors:  C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

4.  Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.

Authors:  Prateeti Khazanie; Gretchen M Heizer; Vic Hasselblad; Paul W Armstrong; Robert M Califf; Justin Ezekowitz; Kenneth Dickstein; Wayne C Levy; John J V McMurray; Marco Metra; W H Wilson Tang; John R Teerlink; Adriaan A Voors; Christopher M O'Connor; Adrian F Hernandez; Randall Starling
Journal:  Am Heart J       Date:  2015-04-11       Impact factor: 4.749

5.  Recognizing worsening chronic heart failure as an entity and an end point in clinical trials.

Authors:  Javed Butler; Eugene Braunwald; Mihai Gheorghiade
Journal:  JAMA       Date:  2014-08-27       Impact factor: 56.272

Review 6.  Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations.

Authors:  Stephen J Greene; Lora AlKhawam; Andrew P Ambrosy; Muthiah Vaduganathan; Robert J Mentz
Journal:  Heart Fail Clin       Date:  2015-08-04       Impact factor: 3.179

Review 7.  The war against heart failure: the Lancet lecture.

Authors:  Eugene Braunwald
Journal:  Lancet       Date:  2014-11-16       Impact factor: 79.321

8.  Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).

Authors:  Stephen J Greene; Adrian F Hernandez; Jie-Lena Sun; Marco Metra; Javed Butler; Andrew P Ambrosy; Justin A Ezekowitz; Randall C Starling; John R Teerlink; Phillip J Schulte; Adriaan A Voors; Paul W Armstrong; Christopher M O'Connor; Robert J Mentz
Journal:  Circ Heart Fail       Date:  2016-09       Impact factor: 8.790

9.  Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Authors:  Adrian F Hernandez; Christopher M O'Connor; Randall C Starling; Craig J Reist; Paul W Armstrong; Kenneth Dickstein; Todd J Lorenz; W Brian Gibler; Vic Hasselblad; Michel Komajda; Barry Massie; John J V McMurray; Markku Nieminen; Jean L Rouleau; Karl Swedberg; Robert M Califf
Journal:  Am Heart J       Date:  2008-12-19       Impact factor: 4.749

10.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

Authors:  Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2014-02-05       Impact factor: 24.094

View more
  5 in total

1.  Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map.

Authors:  Stephen J Greene; Robert M Califf
Journal:  JACC Heart Fail       Date:  2019-02-06       Impact factor: 12.035

2.  Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.

Authors:  Muthiah Vaduganathan; Brian L Claggett; Akshay S Desai; Stefan D Anker; Sergio V Perrone; Stefan Janssens; Davor Milicic; Juan L Arango; Milton Packer; Victor C Shi; Martin P Lefkowitz; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-11-11       Impact factor: 24.094

3.  Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.

Authors:  Peder L Myhre; Muthiah Vaduganathan; Brian L Claggett; Carolyn S P Lam; Akshay S Desai; Inder S Anand; Nancy K Sweitzer; James C Fang; Eileen O'Meara; Sanjiv J Shah; Amil M Shah; Eldrin F Lewis; Jean Rouleau; Bertram Pitt; Scott D Solomon
Journal:  Eur J Heart Fail       Date:  2019-07-22       Impact factor: 15.534

4.  Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries.

Authors:  Fidel Rubagumya; Wilma M Hopman; Bishal Gyawali; Deborah Mukherji; Nazik Hammad; C S Pramesh; Mykola Zubaryev; Alexandru Eniu; Audrey T Tsunoda; Tezer Kutluk; Ajay Aggarwal; Richard Sullivan; Christopher M Booth
Journal:  JAMA Netw Open       Date:  2022-08-01

5.  Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

Authors:  Carolyn S P Lam; João Pedro Ferreira; Egon Pfarr; David Sim; Hiroyuki Tsutsui; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Naveed Sattar; Subodh Verma; Martina Brueckmann; Janet Schnee; Daniel Cotton; Faiez Zannad; Milton Packer
Journal:  Eur Heart J       Date:  2021-11-14       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.